George H. Crossley

George H. Crossley

Auto-generated profile, based on publicly available information

George H. Crossley

Vanderbilt University Medical Center

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2009 in Heart Rhythm
Verified
Journal Article
Closed access
BWBruce L. Wilkoff
Bruce L. Wilkoff
CLCharles J. Love
Charles J. Love
CBCharles L. Byrd
Charles L. Byrd
MBMaria Grazia Bongiorni
Maria Grazia Bongiorni
RCRoger G. Carrillo
Roger G. Carrillo
OWOussama M. Wazni
Oussama M. Wazni

1 March 2011 in JACC
Verified
Journal Article
Closed access
GCGeorge H. Crossley
George H. Crossley
ABAndrew Boyle
Andrew Boyle
HVHolly Vitense
Holly Vitense
YCYanping Chang
Yanping Chang
RMR. Hardwin Mead
R. Hardwin Mead

1 July 2011 in Heart Rhythm
Verified
Journal Article
Closed access
GCGeorge H. Crossley
George H. Crossley
JPJeanne E. Poole
Jeanne E. Poole
MRMarc A. Rozner
Marc A. Rozner
SASamuel J. Asirvatham
Samuel J. Asirvatham
ACAlan Cheng
Alan Cheng
ATAnnemarie Thompson
Annemarie Thompson

1 November 2009 in JACC
Verified
Journal Article
Closed access
GCGeorge H. Crossley
George H. Crossley
JCJane Chen
Jane Chen
WCWassim Choucair
Wassim Choucair
TCTodd J. Cohen
Todd J. Cohen
DGDouglas C. Gohn
Douglas C. Gohn
BWBruce L. Wilkoff
Bruce L. Wilkoff

19 March 2013 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MCMartin R. Cowie
Martin R. Cowie
SSShantanu Sarkar
Shantanu Sarkar
JKJodi Koehler
Jodi Koehler
DWDavid J. Whellan
David J. Whellan
GCGeorge H. Crossley
George H. Crossley
MSMassimo Santini
Massimo Santini
We developed and validated a heart failure (HF) risk score combining daily measurements of multiple device-derived parameters. Heart failure patients from clinical studies with implantable devices were used to form two separate data sets. Daily HF scores were estimated by combining changes in intra-thoracic impedance, atrial fibrillation (AF) burden, rapid rate during AF, %CRT pacing, ventricular tachycardia, night heart rate, heart rate variability, and activity using a Bayesian model. Simulated monthly follow-ups consisted of looking back at the maximum daily HF risk score in the preceding 30 days, categorizing the evaluation as high, medium, or low risk, and evaluating the occurrence of HF hospitalizations in the next 30 days. We used an Anderson–Gill model to compare survival free from HF events in the next 30 days based on risk groups. The development data set consisted of 921 patients with 9790 patient-months of data and 91 months with HF hospitalizations. The validation data set consisted of 1310 patients with 10 655 patient-months of data and 163 months with HF hospitalizations. In the validation data set, 10% of monthly evaluations in 34% of the patients were in the high-risk group. Monthly diagnostic evaluations in the high-risk group were 10 times (adjusted HR: 10.0; 95% CI: 6.4–15.7, P < 0.001) more likely to have an HF hospitalization (event rate of 6.8%) in the next 30 days compared with monthly evaluations in the low-risk group (event rate of 0.6%). An HF score based on implantable device diagnostics can identify increased risk for HF hospitalization in the next 30 days.

23 February 2023 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
GCGeorge H. Crossley
George H. Crossley
JPJonathan P. Piccini
Jonathan P. Piccini
CLColleen Longacre
Colleen Longacre
LHLucas Higuera
Lucas Higuera
KSKurt Stromberg
Kurt Stromberg
MEMikhael F El-Chami
Mikhael F El-Chami
Introduction: The Micra Coverage with Evidence Development (CED) Study is a novel comparative analysis of Micra (leadless VVI) and transvenous single‐chamber ventricular pacemakers (transvenous VVI) using administrative claims data. To compare chronic complications, device reinterventions, heart failure hospitalizations, and all‐cause mortality after 3 years of follow‐up.Methods: US Medicare claims data linked to manufacturer device registration information were used to identify Medicare beneficiaries with a de novo implant of either a Micra VR leadless VVI or transvenous VVI pacemaker from March 9, 2017 to December 31, 2018. Unadjusted and propensity score overlap‐weight adjusted Fine‐Gray competing risk models were used to compare outcomes at 3 years.Results: Leadless VVI patients (N = 6219) had a 32% lower rate of chronic complications and a 41% lower rate of reintervention compared with transvenous VVI patients (N = 10 212) (chronic complication hazard ratio [HR] 0.68; 95% confidence interval [CI], 0.59−0.78; reintervention HR 0.59; 95% CI 0.44−0.78). Infections rates were significantly lower among patients with a leadless VVI (<0.2% vs. 0.7%, p < .0001). Patients with a leadless VVI also had slightly lower rates of heart failure hospitalization (HR 0.90; 95% CI 0.84−0.97). There was no difference in the adjusted 3‐year all‐cause mortality rate (HR 0.97; 95% CI, 0.92−1.03).Conclusion: This nationwide comparative evaluation of leadless VVI versus transvenous VVI de novo pacemaker implants demonstrated that the leadless group had significantly fewer complications, reinterventions, heart failure hospitalizations, and infections than the transvenous group at 3 years, confirming that the previously reported shorter‐term advantages associated with leadless pacing persist and continue to accrue in the medium‐to‐long‐term.